Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June

PR Newswire

TEL AVIV, Israel, May 30, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, today announced that the Company's management will present a company overview at three upcoming scientific and investor conferences in June:

Therapix Biosciences Ltd.

The 7th Annual LD Micro Invitational:

Date:                    

Wednesday, June 7th, 2017

Time:                    

2:30 PM PST

Location:             

Luxe Sunset Boulevard Hotel, Los Angeles, California

Presenter:         

Josh Blacher, Chief Financial Officer

 

The 2017 Marcum MicroCap Conference:

Date:                    

Thursday, June 15th, 2017

Time:                    

10:30 AM EST

Location:             

Grand Hyatt New York

Presenter:         

Josh Blacher, Chief Financial Officer

 

The 27th Annual ICRS Symposium on the Cannabinoids:

Date:                    

June 22nd – 27th, 2017

Venue:                               

Poster Presentation

Location:             

Le Centre Sheraton, Montréal, Canada

Presenter:         

Dr. Elran Haber, Chief Executive Officer and Dr. Adi Zuloff-Shani, Chief Technology Officer

 

About Therapix Biosciences:

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets to the treatment of Tourette's syndrome; and THX-ULD01 targets the high-value and under-served market of mild cognitive impairments. Please visit our website for more information at www.therapixbio.com.

For further information: Investor Contact: Josh Blacher, CFO, Therapix Biosciences, josh@therapixbio.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therapix-biosciences-to-present-at-upcoming-scientific-and-investor-conferences-in-june-300465279.html

SOURCE Therapix Biosciences Ltd

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today